ICU Medical, Inc. was acquired by the State of New Jersey Common Pension Fund D in the third quarter, according to the organization’s recent filing with the Securities and Exchange Commission on Form 13F (NASDAQ: ICUI). The company’s website was consulted to obtain this information. At the end of the reporting period, the company ended up owning a total of 14,767 shares of the medical technology company. This was accomplished by purchasing an additional 2,199 shares during the period. The most recent report that New Jersey State’s Common Pension Fund D filed with the Securities and Exchange Commission indicates that it owned approximately 0.06% of ICU Medical, which at the time had a market value of $2,240,000 would have.
As a result of recent events, hedge funds and other institutional investors have adjusted the percentage of company ownership they hold in their respective portfolios. During the third fiscal quarter, Comerica Bank increased its investment in ICU Medical by 60.1%, bringing its total ownership to 100%. After making additional purchases during the year totaling 6,813 shares, Comerica Bank now owns 18,156 shares of the company with a market value of $2,575,000. Raymond James & Associates’ holdings in ICU Medical increased 31.0 percent overall in the third quarter as a result of the company’s acquisitions. Raymond James & Associates now owns 100,181 shares of the medical instrument maker after buying an additional 23,679 shares last quarter. Based on the current stock price, Raymond James & Associates’ holdings are valued at $15,087,000. Raymond James Financial Services Advisors Inc. increased the percentage of ICU Medical stock it owned by 85.4% in the third quarter. Raymond James Financial Services Advisors Inc. now owns 5,841 shares of the medical instrument maker, valued at $880,000, after the company bought 2,690 shares in the previous quarter. The last business quarter was used to purchase these shares. The Louisiana State Employees Retirement System added one new ICU medical position during the fiscal third quarter. The annual salary for this position was approximately $798,000. During the third quarter, Boston Trust Walden Corporation increased its holdings in ICU Medical stock by 3.8%, making this the last and most important point. Boston Trust Walden Corp now owns 239,935 shares of the medical instrument maker, valued at $36,135,000, after purchasing an additional 8,736 shares in the previous quarter. Large financial institutions own most of the company’s shares, accounting for 93.88 percent of the total.
On November 15, the last day of trading, Vice President Virginia Ruth Sanzone sold 325 shares of the company. Accordingly, this news was published on November 15th. The average price paid per share was $160.12 in the transaction, which resulted in a total payment of $52,039.00. As a result of the transaction, the company’s vice president now owns 3,046 shares of the company’s shares, which are collectively valued at $487,725.52. If you follow the link that takes you to a filing with the SEC, you have the opportunity to obtain additional information about the transaction. The company’s insiders hold 7.30% of the total number of shares outstanding.
Several different stock market analysts have each written their research on ICUI stocks which can be found here. KeyCorp announced in a research report published on November 8 that they would lower their price target on ICU Medical shares to $200.00 from $225.00. StockNews.com advised readers to “sell” their existing positions in ICU Medical stock in an article published Thursday, November 17 as part of a research report. In a research note published on November 8, Raymond James downgraded his rating on ICU Medical stocks, changing it from outperform to market perform.
ICUI first traded at $176.82 on Wednesday. ICU Medical, Inc. can be purchased for between $129.90 and $251.73 for a year. The prices can fluctuate. There is 1.17 times faster translation than current translation and 2.45 times higher current translation than fast translation. The debt-to-equity ratio is 0.81 times higher than the quick ratio. The 50-day moving averages are $159.38 and the 200-day moving averages are $159.96 for the company. The stock has a price to earnings ratio of -113.35 and its beta value is 0.53. Both values are negative. The value of the company’s shares on the market is approximately $4.24 billion.
ICU Medical, whose shares are publicly traded and whose symbol can be found on NASDAQ as ICUI, announced its recent gains on November 7th. The medical supplies and equipment retailer reported earnings of $1.53 per share (EPS) for the quarter, which was $0.38 above the consensus expectation of $1.15 per share for the company’s earnings lies. Analysts’ forecasts for the company’s revenue for the quarter ranged from $562.90 million to $597.86 million. Although ICU Medical had a negative net margin of 1.90%, the company still had a positive return on equity of 6.51%. According to sell-side analyst forecasts, ICU Medical, Inc. is expected to post earnings of $5.18 per share in 2018.
ICU Medical, Inc. and its subsidiaries are responsible for the design, manufacture and distribution of the medical devices used in the delivery of infusion therapy and critical care procedures worldwide. Infusion therapy products manufactured by the Company include an antimicrobial barrier cap for hemodialysis catheters called ClearGuard HD; Needle-free products sold under the MicroClave, MicroClave Clear and NanoClave brands; neutron catheter patency devices; SwabCap and SwabTip disinfection caps; Tego hemodialysis connectors; ChemoClave and ChemoLock closed system transfer devices; and Diana’s Dangerous Drug Manufacturing System for manufacturing Dangerous Drugs.